Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta-analysis with meta-regression - PubMed (original) (raw)

Meta-Analysis

. 2020 Aug;22(8):1397-1405.

doi: 10.1111/dom.14047. Epub 2020 May 7.

Affiliations

Meta-Analysis

Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta-analysis with meta-regression

Dario Giugliano et al. Diabetes Obes Metab. 2020 Aug.

Abstract

Aim: In order to disclose relations between reduction of haemoglobin A1c (HbA1c) levels and risk of major cardiovascular events (MACE), we performed a meta-analysis with metaregression of all cardiovascular outcome trials (CVOTs) so far published in patients with type 2 diabetes (T2D).

Materials and methods: An electronic search up to February 10, 2020 was conducted to determine eligible trials. Pooled summary estimates and 95% confidence intervals (CI) were calculated according to the random effects model using the Paule-Mandel method; restricted maximum likelihood estimators were used to estimate model parameters in the metaregression.

Results: The 15 CVOTs included evaluated 138,250 patients. In the pooled analysis, the risk of MACE was significantly reduced by 9% (hazard ratio, HR = 0.91, 0.87-0.95, P <0.001) as compared with placebo, with significant heterogeneity between trials (I2 = 44%, P = 0.060) There was a robust relation between the reduction in achieved HbA1c at the end of the trial and the HR reduction for MACE (beta = -0.3169, P = 0.029), explaining most (78%) of the between-study variance; this relation was totally driven by the risk reduction of non-fatal stroke only, which explained 100% of between-study variance, and apparently restricted to the class of glucagon-like peptide 1 receptor agonists (GLP-1RAs). There was no relation between the reduction in achieved HbA1c and the HR for heart failure (variance explained = 0%) or all-cause mortality (variance explained = 6%).

Conclusion: The blood glucose reduction observed in CVOTs may play some role in reducing the risk of non-fatal stroke, at least during treatment with GLP-1RAs, without affecting the other two components of MACE.

Keywords: cardiovascular outcome trials, glucagon-like peptide-1 receptor agonists, major cardiovascular events, meta-regression, non-fatal stroke, type 2 diabetes.

© 2020 John Wiley & Sons Ltd.

PubMed Disclaimer

Similar articles

Cited by

References

REFERENCES

    1. Food and Drug Administration. Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, Maryland: Food and Drug Administration, December 2008. www.fda.gov/downloads/Drugs/Guidances/ucm071627.pdf. Accessed March 24, 2020.
    1. Giugliano D, Meier JJ, Esposito K. Heart failure and type 2 diabetes: from CVOTs, with hope. Diabetes Obes Metab. 2019;21:1081-1087.
    1. Singh M, Sharma R, Kumar A. Safety of SGLT2 inhibitors in patients with diabetes mellitus. Curr Drug Saf. 2019;14:87-93.
    1. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and America College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2020 executive summary. Endocr Pract. 2020;26:107-139.
    1. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical Care in Diabetes-2020. Diabetes Care. 2020;43(suppl 1):S111-S134.

Publication types

MeSH terms

Substances

LinkOut - more resources